Fidelity SPDR Advertisement
Home > Boards > US OTC > Food - Processing and Agriculture >

Plandai Biotechnology, Inc. (PLPL)

PLPL RSS Feed
Add PLPL Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Aston Martin
Search This Board:
Last Post: 11/21/2014 6:14:48 PM - Followers: 187 - Board type: Free - Posts Today: 0


www.plandaibiotech.com
 

Information Update May 20, 2014

Movie by Plandai:

http://vimeo.com/95723836


 

Plandaí and Cannabis – What is Our Role?

When Plandaí first announced its intention to produce a Phytofare™ Cannabinoid Extract, we were inundated with phone calls and emails—the majority of which wanted to know when and where they could buy some.  Since that time, we’ve read different articles and blog posts speculating that Plandaí is growing marijuana on its South Africa plantation and importing its extract to Washington under the Diego Pellicer brand name. 

With all of this misinformation out there, we felt it appropriate to “set the record straight” with respect to Plandaí and its involvement in the marijuana industry.

First, Plandaí is NOT presently producing any type of cannabis extract nor are we farming cannabis in South Africa, Washington or anywhere else.  There are many reasons for this, but primarily we recognize that cannabis cultivation and extract production is illegal—everywhere—unless you have special permission from the government.  Notwithstanding recent legislation in Washington and Colorado, growing, processing, possessing and selling marijuana in any form is still illegal on the federal level.  Plandaí has no intention of crossing this line.  Internationally, growing marijuana is illegal, especially in South Africa and other countries where we operate.

Initially, our attorneys believed we could set up a lab and begin testing in Washington.  We set this process in motion by designing the equipment and reaching out to local scientists and researchers.  We then determined that, if followed through upon, our activities could potentially violate federal laws and we immediately halted any efforts to produce an extract in the US.

With that being said, Plandaí believes that cannabis shows great medical potential.  Unfortunately, very little testing has been done in a true, double-blind, controlled human clinical environment.  Much of what we know is either anecdotal or backed by small lab-scale studies.  We have developed the science that will allow us to produce a highly bioavailable cannabinoid complex.  This new product should enable us to deliver a clinical dose of cannabinoids directly to human tissue and, theoretically, even cross the blood-brain barrier, enabling us to treat neuron disorders.  Without testing, however, this is all theoretical.   

Plandaí is actively working with several government agencies in hopes of being granted permission to commence testing our cannabinoid product.  Once this permission is received, it will take us about ninety days to set up an extraction lab and produce the first extract.  This extract will then be tested for purity and undergo a full chemical profile.  Only then will be begin animal studies to determine what, if any, medicinal benefits are present.  Favorable lab studies will eventually lead to human clinical trials but, again, only with proper government sanctioning. 

We believe that favorable clinical trials will eventually pave the way for government acceptance.  Especially for products like Plandaí’s which will have no psychoactive effects.  Once we reach that point, we will have several decisions to make: Do we produce an extract locally? Do we license the technology to a third party? Do we farm our own product or purchase from a local grower?  We cannot begin to answer these questions until we first have clinical results and then take account of the legal landscape at such future date.

The takeaway for our investors is that Plandaí remains committed to conducting ongoing research with a variety of different plants including cannabis and that this research will go forward as fast as the legal climate permits.  Until such time, we remain committed to obeying the laws—federal, state, and international—while we continue to champion for changes to those laws and establish industry standards.  We have a fiduciary responsibility to our shareholders to ensure that our company is built on a solid foundation of science, ethics, frugality, and adherence to the laws of the land.

We will continue to keep our shareholders aware of any changes to legislation and any government-approved dispensations we obtain.

 
 
 









Quarterly report December 2013
http://www.sec.gov/Archives/edgar/data/1317880/000126246313000072/plpl10q.htm
 
Detailled business philosophy and profile of Plandai Biotechnology
www.plandaibiotech.com/PB_webbrochure_lores/index.html#/1/



Interview of CEO (Audio / February 14, 2012)
http://thestockradio.com/plpl-plandai-biotechnology-inc-v-p-global-director-of-marketing-sales-callum-baylis-duffield/

 
 

Security Details

 

Plandai Biotechnology, Inc. is a fully reporting SEC company, publicly traded on the OTC Market under the symbol, "PLPL". As such, Business, operational and financial information on PLPL is fully transparent and available to public view.  

www.otcmarkets.com

                                                                                                            A/S :        500 million confirmed / State of Nevada

                                                                                                            O/S :       Approx. 125.000.000
                                                                                                                                                                                                         
                                                                                                                                                                                  Free Float:        unknown
 

Incorporated in: NV,USA

Year of Inc.:  2012

 

Transfer Agent

Signature Stock Transfer, Inc.

Transfer Agent, 2632 Coachlight Ct., Plano, TX, 75093

972-612-4120

SignatureStock@aol.com



 

Plandaí Biotechnology, Inc. Provides Shareholder Update on Completion of the Company’s Production Facility and Start of Commercial Production
August, 6, 2014
The Update Also Provides New Information on Studies Involving Plandaí Products, Including an Upcoming Phase II Human Clinical Trial


SEATTLE, WA / ACCESSWIRE / August 6, 2014 / Plandaí Biotechnology, Inc. (PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today provided an update to shareholders that covers topics including the completion and optimization of the company’s state-of-the-art production facility in South Africa and the schedule for commencement of commercial production at the facility.

According to company spokesperson Louise Willemse, contractors are expected to finish all installation work at the company’s production facility on the Senteeko Tea Estate in South Africa between August 8 and Aug 15, 2014. The installation work includes all electrical, steam lines, equipment installation, and boiler system.

Engineers from the Indian contractor are scheduled to arrive on-site during the week of August 17 to complete the optimization and to initiate start-up of the facility. This process is anticipated to be complete during the first half of September 2014.

Commercial production of the Phytofare(TM) Catechin extract is then expected to commence with the first green tea crop of the season, which is entirely weather dependent but is anticipated to begin sometime in late September 2014 and continue through May of 2015. During the next winter season in South Africa, June through August 2015, the Company will begin processing Eureka lemons to produce approximately 200 kg of Phytofare(TM) Limonoid Glycoside Complex per day.

In addition to releasing the factory update, Plandaí also announced that the first two legs of the human clinical trial on the oral bioavailability of the company’s Phytofare™ Catechin Complex have been completed and results are expected to be released during the week of August 17, 2014. The third and final leg of the study will take place using Phytofare™ extract produced at the Senteeko facility and then entrapped in Pheroid® by scientists at North-West University in Potchefstroom, South Africa.

Concurrent with the third leg of the bioavailability study, Plandaí expects to commence a study testing the effects of Phytofare(TM) Catechin Complex in inducing weight loss. The study is being designed as a Phase II human clinical trial and will involve 100 patients over 90 days in a double-blind protocol.




Plandai Biotechnology Names Diego Pellicer Co-Founder and CannabisPioneer Jamen Shively as Vice President of Global Marketing

Recently Appointed Board Member Joins Management Team to Oversee Branding and Product Strategy

NEW YORK, NY, Feb 20, 2014 (Menafn - Marketwired via COMTEX) --Plandai Biotechnology, Inc. (otcqb:PLPL), a producer of highlybioavailable plant extracts for industries including health,wellness, nutraceutical, and pharmaceutical, announced today thatJamen Shively, a leading voice in the burgeoning marijuana industryand recently appointed Board Member of Plandai, has been named asVice President of Global Marketing.

As VP-Global Marketing, the company released, Mr. Shively will beresponsible for building brand awareness and marketing strategy forall of Plandai's operations including the Diego Pellicer(R) medicalcannabis line as well as the Phytofare(TM) botanical extracts such asthe Green Tea Catechin Complex and the Limonoid Glycoside Complex.

Roger Duffield, Chief Executive Officer of Plandai, commented on Mr.Shively's new position within the Company, "We're excited to bringJamen fully into the Plandai fold. He did a brilliant job buildingthe Diego Pellicer brand, and we're confident that he will build onthis experience as we launch the first of our products in the comingweeks. Our goal is to become the leading name in highly bioavailablebotanical extracts for both nutraceutical and pharmaceuticalapplications. Jamen has the vision and expertise to help further ustowards that end."

Mr. Shively stated, "I could not be more pleased to come aboardPlandai, first as a Director and now as a full-time member of themanagement team. Plandai is uniquely positioned in that it has noreal direct competition -- no one else in the market is selling highbioavailability plant extracts. Consumers are starting to demand morefrom their vitamins and supplements and asking to what extent are thebillions of dollars being spent on such products actually increasinghealth and wellness. My role with Plandai, as I see it, is to educatethe consumer that they need to demand more from their supplementswhile also telling the Plandai story. We have a unique opportunitywith Plandai's technology to fundamentally change how we addresswellness, health and prevention through natural, botanicalsolutions."

He added, "I am also extremely excited about the application ofPlandai's technologies to cannabis, which I believe willrevolutionize the application of cannabis to preventive andtherapeutic health, under the Diego Pellicer brand. This is theopportunity of a lifetime for me and for my colleagues at Plandai tochange the world by improving the health and wellness of mankindthrough 100% natural plant extracts. We are unlocking the potentialof nature's plant nutrients for humans and animals alike."

Jamen Shively, age 45, has a background in engineering and marketing,with specialties in artificial intelligence, the modeling andoptimization of complex networks, and the creation and positioning ofnew categories of products and services. Jamen co-founded DiegoPellicer Inc. in 2012 and built the brand from zero to the #1 mostrecognized brand of cannabis in the world in less than one year.Prior to founding Diego Pellicer, Jamen was a Corporate StategyManager for Microsoft from 2003 to 2009, where he focused on thecreation and development of new categories of software products andonline services. Preceding his Microsoft career he headed ShivelyInternational Inc., which built and operated both cybercafes andeducational computer centers in Mexico. Just prior to founding DiegoPellicer Inc., Jamen founded and headed the online marketplace forthe specialty food industry, Findood, winning first place in theNorthwest Entrepreneur Network's First Look Forum Competition for thetop new startup in 2010. Jamen completed his undergraduate work atU.C. Berkeley in Civil Engineering, and did graduate work at M.I.T.and U.C. Berkeley in Civil Engineering and Materials Science. He is aFellow of the National Science Foundation.

Plandai Biotechnology Names Diego Pellicer Co-Founder and Cannabis Pioneer Jamen Shively as Vice President of Global Marketing

PLPL, BIOGY | February 20, 2014

NEW YORK, NY- via eTeligis (Feb 20, 2014) -  Planda Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, announced today that Jamen Shively, a leading voice in the burgeoning marijuana industry and recently appointed Board Member of Planda, has been named as Vice President of Global Marketing.

 

As VP-Global Marketing, the company released, Mr. Shively will be responsible for building brand awareness and marketing strategy for all of Planda's operations including the Diego Pellicer medical cannabis line as well as the Phytofare botanical extracts such as the Green Tea Catechin Complex and the Limonoid Glycoside Complex.

 

Roger Duffield, Chief Executive Officer of Planda, commented on Mr. Shively's new position within the Company, "We're excited to bring Jamen fully into the Planda fold. He did a brilliant job building the Diego Pellicer brand, and we're confident that he will build on this experience as we launch the first of our products in the coming weeks. Our goal is to become the leading name in highly bioavailable botanical extracts for both nutraceutical and pharmaceutical applications. Jamen has the vision and expertise to help further us towards that end." 

 

Mr. Shively stated, "I could not be more pleased to come aboard Planda, first as a Director and now as a full-time member of the management team. Planda is uniquely positioned in that it has no real direct competition -- no one else in the market is selling high bioavailability plant extracts. Consumers are starting to demand more from their vitamins and supplements and asking to what extent are the billions of dollars being spent on such products actually increasing health and wellness. My role with Planda, as I see it, is to educate the consumer that they need to demand more from their supplements while also telling the Planda story. We have a unique opportunity with Planda's technology to fundamentally change how we address wellness, health and prevention through natural, botanical solutions." 

 

He added, "I am also extremely excited about the application of Planda's technologies to cannabis, which I believe will revolutionize the application of cannabis to preventive and therapeutic health, under the Diego Pellicer brand. This is the opportunity of a lifetime for me and for my colleagues at Plandai to change the world by improving the health and wellness of mankind through 100% natural plant extracts. We are unlocking the potential of nature's plant nutrients for humans and animals alike."

 

Jamen Shively, age 45, has a background in engineering and marketing, with specialties in artificial intelligence, the modeling and optimization of complex networks, and the creation and positioning of new categories of products and services. Jamen co-founded Diego Pellicer Inc. in 2012 and built the brand from zero to the #1 most recognized brand of cannabis in the world in less than one year. Prior to founding Diego Pellicer, Jamen was a Corporate Stategy Manager for Microsoft from 2003 to 2009, where he focused on the creation and development of new categories of software products and online services. Preceding his Microsoft career he headed Shively International Inc., which built and operated both cybercafs and educational computer centers in Mexico. Just prior to founding Diego Pellicer Inc., Jamen founded and headed the online marketplace for the specialty food industry, Findood, winning first place in the Northwest Entrepreneur Network's First Look Forum Competition for the top new startup in 2010. Jamen completed his undergraduate work at U.C. Berkeley in Civil Engineering, and did graduate work at M.I.T. and U.C. Berkeley in Civil Engineering and Materials Science. He is a Fellow of the National Science Foundation.


Read more at http://www.stockhouse.com/news/press-releases/2014/02/20/plandai-biotechnology-names-diego-pellicer-co-founder-and-cannabis-pioneer#bRlEkKORllERl0oV.99
 

February 14, 2014 09:00 ET

Marijuana Entrepreneur Jamen Shively Goes Public With Plandai Biotechnology, Inc.

NEW YORK, NY--(Marketwired - Feb 14, 2014) - If Plandaí Biotechnology (OTCQB: PLPL) investors liked the idea of Diego Pellicer co-founder Jamen Shively working with the company from the outside, then they'll love the idea that he's now on the inside of this public biotech. Jamen Shively, a former Microsoft executive turned marijuana entrepreneur, has gone public being named to the Board of Directors at Plandaí. 

His experience at Microsoft alone makes this a great business move, but the media's attraction to Shively's confident approach to capturing 40 percent of the worldwide marijuana market makes his addition inside any public company a really big deal. Hopefully Plandaí is prepared for the media frenzy that is likely to occur when the national press that showed up en masse to his 2013 press conference, learns of Shively's appointment to the Board.

Plandaí recently completed a deal with Diego Pellicer, Inc. that allows it to market its Phytofare™ Cannabis extracts under the Diego Pellicer Gold brand, so it makes a lot of sense to Roger Duffield, CEO of Plandaí, to have Jamen Shively spearheading that branding process from inside the company. "Jamen brings a wealth of experience in both engineering and branding to Plandaí not to mention his bold leadership in the Cannabis field." 

It's that bold leadership that makes Shively so attractive to the media and his "first to mind" approach will keep him in the headlines as the marijuana debate unfolds. With headlines like: "Ex-Microsoft Employee Is Going Big In The Marijuana Business," "Jamen Shively, Former Microsoft Manager, To Launch 'Premium Marijuana' Business In Washington," and "Ex-Microsoftie Jamen Shively Is Building A Marijuana Empire," Shively is clearly proving his point. 

The man some are calling the "Bill Gates of Cannabis" has the attention of the media and can likely command a microphone or writer just about any time he wants. For Plandaí and its investors, Shively's not a bad guy to have around your public company, especially in a burgeoning market.

And, this is exactly what Duffield understands as his company looks to move into production and sales of its Cannabis extracts. The CEO said, "As a member of Plandaí's Board, Jamen will be instrumental in helping shape our corporate policy and direction as we move from being a research company into production and sales in the coming months."


Plandai Biotechnology Names Diego Pellicer Co-Founder and Cannabis Pioneer Jamen Shively as Vice President of Global Marketing

PLPL, BIOGY | February 20, 2014

NEW YORK, NY- via eTeligis (Feb 20, 2014) -  Planda Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, announced today that Jamen Shively, a leading voice in the burgeoning marijuana industry and recently appointed Board Member of Planda, has been named as Vice President of Global Marketing.

 

As VP-Global Marketing, the company released, Mr. Shively will be responsible for building brand awareness and marketing strategy for all of Planda's operations including the Diego Pellicer medical cannabis line as well as the Phytofare botanical extracts such as the Green Tea Catechin Complex and the Limonoid Glycoside Complex.

 

Roger Duffield, Chief Executive Officer of Planda, commented on Mr. Shively's new position within the Company, "We're excited to bring Jamen fully into the Planda fold. He did a brilliant job building the Diego Pellicer brand, and we're confident that he will build on this experience as we launch the first of our products in the coming weeks. Our goal is to become the leading name in highly bioavailable botanical extracts for both nutraceutical and pharmaceutical applications. Jamen has the vision and expertise to help further us towards that end." 

 

Mr. Shively stated, "I could not be more pleased to come aboard Planda, first as a Director and now as a full-time member of the management team. Planda is uniquely positioned in that it has no real direct competition -- no one else in the market is selling high bioavailability plant extracts. Consumers are starting to demand more from their vitamins and supplements and asking to what extent are the billions of dollars being spent on such products actually increasing health and wellness. My role with Planda, as I see it, is to educate the consumer that they need to demand more from their supplements while also telling the Planda story. We have a unique opportunity with Planda's technology to fundamentally change how we address wellness, health and prevention through natural, botanical solutions." 

 

He added, "I am also extremely excited about the application of Planda's technologies to cannabis, which I believe will revolutionize the application of cannabis to preventive and therapeutic health, under the Diego Pellicer brand. This is the opportunity of a lifetime for me and for my colleagues at Plandai to change the world by improving the health and wellness of mankind through 100% natural plant extracts. We are unlocking the potential of nature's plant nutrients for humans and animals alike."

 

Jamen Shively, age 45, has a background in engineering and marketing, with specialties in artificial intelligence, the modeling and optimization of complex networks, and the creation and positioning of new categories of products and services. Jamen co-founded Diego Pellicer Inc. in 2012 and built the brand from zero to the #1 most recognized brand of cannabis in the world in less than one year. Prior to founding Diego Pellicer, Jamen was a Corporate Stategy Manager for Microsoft from 2003 to 2009, where he focused on the creation and development of new categories of software products and online services. Preceding his Microsoft career he headed Shively International Inc., which built and operated both cybercafs and educational computer centers in Mexico. Just prior to founding Diego Pellicer Inc., Jamen founded and headed the online marketplace for the specialty food industry, Findood, winning first place in the Northwest Entrepreneur Network's First Look Forum Competition for the top new startup in 2010. Jamen completed his undergraduate work at U.C. Berkeley in Civil Engineering, and did graduate work at M.I.T. and U.C. Berkeley in Civil Engineering and Materials Science. He is a Fellow of the National Science Foundation.


Read more at http://www.stockhouse.com/news/press-releases/2014/02/20/plandai-biotechnology-names-diego-pellicer-co-founder-and-cannabis-pioneer#bRlEkKORllERl0oV.99

 

Plandai Biotechnology Names Diego Pellicer Co-Founder and Cannabis Pioneer Jamen Shively as Vice President of Global Marketing

PLPL, BIOGY | February 20, 2014

NEW YORK, NY- via eTeligis (Feb 20, 2014) -  Planda Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, announced today that Jamen Shively, a leading voice in the burgeoning marijuana industry and recently appointed Board Member of Planda, has been named as Vice President of Global Marketing.

 

As VP-Global Marketing, the company released, Mr. Shively will be responsible for building brand awareness and marketing strategy for all of Planda's operations including the Diego Pellicer medical cannabis line as well as the Phytofare botanical extracts such as the Green Tea Catechin Complex and the Limonoid Glycoside Complex.

 

Roger Duffield, Chief Executive Officer of Planda, commented on Mr. Shively's new position within the Company, "We're excited to bring Jamen fully into the Planda fold. He did a brilliant job building the Diego Pellicer brand, and we're confident that he will build on this experience as we launch the first of our products in the coming weeks. Our goal is to become the leading name in highly bioavailable botanical extracts for both nutraceutical and pharmaceutical applications. Jamen has the vision and expertise to help further us towards that end." 

 

Mr. Shively stated, "I could not be more pleased to come aboard Planda, first as a Director and now as a full-time member of the management team. Planda is uniquely positioned in that it has no real direct competition -- no one else in the market is selling high bioavailability plant extracts. Consumers are starting to demand more from their vitamins and supplements and asking to what extent are the billions of dollars being spent on such products actually increasing health and wellness. My role with Planda, as I see it, is to educate the consumer that they need to demand more from their supplements while also telling the Planda story. We have a unique opportunity with Planda's technology to fundamentally change how we address wellness, health and prevention through natural, botanical solutions." 

 

He added, "I am also extremely excited about the application of Planda's technologies to cannabis, which I believe will revolutionize the application of cannabis to preventive and therapeutic health, under the Diego Pellicer brand. This is the opportunity of a lifetime for me and for my colleagues at Plandai to change the world by improving the health and wellness of mankind through 100% natural plant extracts. We are unlocking the potential of nature's plant nutrients for humans and animals alike."

 

Jamen Shively, age 45, has a background in engineering and marketing, with specialties in artificial intelligence, the modeling and optimization of complex networks, and the creation and positioning of new categories of products and services. Jamen co-founded Diego Pellicer Inc. in 2012 and built the brand from zero to the #1 most recognized brand of cannabis in the world in less than one year. Prior to founding Diego Pellicer, Jamen was a Corporate Stategy Manager for Microsoft from 2003 to 2009, where he focused on the creation and development of new categories of software products and online services. Preceding his Microsoft career he headed Shively International Inc., which built and operated both cybercafs and educational computer centers in Mexico. Just prior to founding Diego Pellicer Inc., Jamen founded and headed the online marketplace for the specialty food industry, Findood, winning first place in the Northwest Entrepreneur Network's First Look Forum Competition for the top new startup in 2010. Jamen completed his undergraduate work at U.C. Berkeley in Civil Engineering, and did graduate work at M.I.T. and U.C. Berkeley in Civil Engineering and Materials Science. He is a Fellow of the National Science Foundation.


Read more at http://www.stockhouse.com/news/press-releases/2014/02/20/plandai-biotechnology-names-diego-pellicer-co-founder-and-cannabis-pioneer#bRlEkKORllERl0oV.99

For press releases please visit: www.plandaibiotech.com/press-release.html

_______________________________________________________________________________________________________________________________________________________________________________________________________________________________________
 

Management Team
Roger Duffield
President, Chief Executive officer and member of the Board of Directors

Callum Baylis-Duffield
Vice-President and Global Director: Marketing
Sales

David Rzepnicki
Chief Financial Officer and member of the Board of Directors

Tim Matula
Investor Relations and member of the Board of Directors

Contact:
Corporate Headquarters
Address: 2226 Eastlake Ave E, #156
Seattle, Washington, 98102, USA
Phone: (425) 466-0212
Website:
http://www.plandaibiotech.com
Email: Info@plandaibiotech.com



LIST OF RESEARCHES, COVERAGE, ETC. :


http://www.cpreports.com/2013/05/22/ray-dirks-research-plandai-biotechnology-plpl-may-23-2013-by-ray-dirks/
............................... 
" Ray Dirks Research is projecting price targets for Plandaí Biotechnology, Inc. of $1.00 for the Short Term (6 to 9 Months) and $3.00 for the Long Term (1 to 3 Years)."


http://www.goldmanresearch.com/Search.html?ordering=&searchphrase=all&searchword=plandai
................................  "As commercialization and further testing occurs, the shares should approach the $2.00 level in 2013."

http://www.otcjournal.com
..................".....I've always had a 2013 price target on PLPL of $1.00. Based on the last 10 days, it looks like I'll be right on this one. I hope you own PLPL."

http://www.stockmarketmediagroup.com/wp-content/uploads/2013/04/Plandai-Biotechnology-Inc.-PLPL-Research-Report.pdf

 

                                                                                                                                                    PLANDAI BIOTECHNOLOGY at Africa                                                  

          
 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PLPL
Current Price
Volume:
Bid Ask Day's Range
Wiki
PLPL News: Quarterly Report (10-q) 11/14/2014 04:20:07 PM
PLPL News: Annual Report (10-k) 10/14/2014 09:59:18 AM
PLPL News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 09/29/2014 04:25:04 PM
PLPL News: Current Report Filing (8-k) 09/09/2014 04:44:55 PM
PLPL News: FDA Exemption Has Plandai Biotechnology Heading Into Third Quarter Ready to Commence Sales of First Phytofare(TM) Product 06/26/2014 09:00:00 AM
PostSubject
#11220  Sticky Note PLPL - MUST WATCH: Aston Martin 05/20/14 09:18:30 AM
#12019   This happens at all listed non-revenue-pennystock. I am Aston Martin 11/21/14 06:14:48 PM
#12018   i remember in the old days plpl was tmonkey 11/21/14 12:08:20 PM
#12017   "SMMG is compensated $3,500 per month by Plandai Aston Martin 11/20/14 07:42:27 PM
#12016   SMMG is getting rich off PLPL huh brandao 11/20/14 05:33:08 PM
#12015   News: Plandai Biotechnology Could Offer Potential Anti-Viral Protection Aston Martin 11/19/14 12:56:45 PM
#12014   Shively is in PLPL since February - what Aston Martin 11/19/14 11:59:23 AM
#12013   Possible. Agree. Money to survive will be the Aston Martin 11/17/14 12:33:24 PM
#12012   Another view of predictions. tomatotom 11/17/14 11:58:16 AM
#12011   Nice you ask for my opinion - even Aston Martin 11/17/14 11:31:31 AM
#12010   So what is your prediction for 2015? wallstreetbuyer 11/17/14 12:00:24 AM
#12008   Dude stop makes me sad lol I just brandao 11/14/14 07:19:54 PM
#12007   Guess you are kidding. 10Q of today: Aston Martin 11/14/14 05:46:18 PM
#12006   chart looks ready real soon. jjr04001 11/14/14 03:11:48 PM
#12005   Endless delays: now sales of products in december Aston Martin 11/11/14 04:19:52 PM
#12004   NEWS! http://finance.yahoo.com/news/plandai-biotechnology-collaboration-offers-o Pierrocks 11/10/14 09:22:34 AM
#12003   Uruguay news Anyone see the wallstreetbuyer 11/08/14 09:02:34 PM
#12002   ...and I think it is important to notice Aston Martin 11/06/14 01:33:22 PM
#12001   Goodluck with that Uruguay facility producing anything. brandao 11/06/14 01:10:48 PM
#12000   I think it's important to differentiate from the riberyknuckles 11/06/14 04:25:30 AM
#11999   Smh brandao 11/05/14 10:24:00 PM
#11998   http://finance.yahoo.com/news/plandai-biotechnology-cannabis-research-gets-14000 Aston Martin 11/05/14 12:26:09 PM
#11997   "The CEO says he expects it will take foreveralone 11/05/14 11:49:26 AM
#11996   can you post the link to this? foreveralone 11/05/14 11:43:49 AM
#11995   "...The CEO says he expects it will take Aston Martin 11/05/14 10:48:47 AM
#11994   Great timing for news today Huh?$$$ http://finance.yahoo.com/news/plandai-biotec Pierrocks 11/05/14 09:24:26 AM
#11993   If PLPL does not move its a§§ soon, Aston Martin 11/04/14 03:44:21 PM
#11992   election sector mojo should start this stock... LAmerica 11/03/14 07:15:25 PM
#11991   Do you really take such exxegerated prediction serious? Aston Martin 11/03/14 04:56:14 PM
#11990   The co. would need an EPS of .50 tradetrak 11/03/14 03:13:58 PM
#11989   you should not take posts here serious - Aston Martin 11/03/14 11:38:58 AM
#11988   Why it is fine that no sale wallstreetbuyer 11/02/14 11:54:36 AM
#11987   for some everything seems to be right whatever Aston Martin 11/02/14 06:28:10 AM
#11986   $PLPL Thats fine with me Aston..Just ride the captainscotty 11/02/14 05:51:37 AM
#11985   I believe we will have first sales in Aston Martin 11/01/14 03:05:03 PM
#11984   Yes. Now for some sales... :) tradetrak 11/01/14 01:06:47 PM
#11983   $PLPL Thanks TT >>>>PLANDAI WORLD WIDE<<<<.....:-} captainscotty 10/31/14 03:05:57 PM
#11982   Crap news no one cares about Uruguay ... brandao 10/30/14 12:43:54 PM
#11981   Plandai Biotechnology, Inc. Receives Approval to Grow Cannabis tomatotom 10/30/14 09:32:37 AM
#11980   Partly I agree, but not in "They are Aston Martin 10/30/14 06:56:06 AM
#11979   Why I invested in PLANDAI BIOTECH, because I foreveralone 10/30/14 05:46:47 AM
#11978   I guess Jamen is a man of action Blazing Stock 10/29/14 06:12:10 PM
#11977   SNAP... and PLPL has a subsidary at Uruguay Aston Martin 10/29/14 01:17:59 PM
#11976   Yes. Very interesting news. I know Shively hasn't tradetrak 10/29/14 10:57:30 AM
#11975   News out:) http://finance.yahoo.com/news/plandai-biotechnology-inc-receives-app Pierrocks 10/29/14 09:11:30 AM
#11974   Well, it might be right that such negative Aston Martin 10/28/14 06:02:39 PM
#11973   PLPL CHART >> l2 hunter 10/28/14 04:26:46 PM
#11972   It's pretty much the typical cautionary language from tradetrak 10/28/14 04:05:34 PM
#11971   I'll only enjoy when this puppy shoots up brandao 10/28/14 03:38:09 PM
#11970   I'm in - sounds like a great idea. :) tradetrak 10/27/14 10:19:40 PM
#11969   NICE day here:) How about we just enjoy Pierrocks 10/27/14 06:52:37 PM
PostSubject